Rule 144 Notice: 31,694 Common Shares Planned Sale on NYSE
Rhea-AI Filing Summary
Form 144 notice for proposed sale of common stock. The filing reports an intended sale of 31,694 shares of common stock with an aggregate market value of $1,281,705.00. The securities represent shares acquired on 12/04/2023 through vesting/deferred compensation. The filer lists 110,537,295 shares outstanding and an approximate sale date of 08/19/2025 on the NYSE. The broker name and address shown is "THE CHARLES SCHWAB CORPORATION, 3000 Schwab Way, Westlake TX 76262." The filing indicates no securities sold in the past three months and includes the standard signer representation about absence of undisclosed material adverse information.
Positive
- Clear compliance with Rule 144 disclosure requirements: acquisition date, nature, and planned sale date are provided
- No sales in past three months, which reduces aggregation concerns under Rule 144
Negative
- None.
Insights
TL;DR: Routine insider sale notice of vested compensation shares; size is small relative to total outstanding and appears procedural.
The filing notifies the SEC of a proposed sale of 31,694 common shares valued at $1.28 million, acquired via vesting/deferred compensation on 12/04/2023. With 110.5 million shares outstanding, the position represents roughly 0.03% of outstanding stock, indicating the transaction is unlikely to be materially dilutive or market-moving. The notice shows no related sales in the prior three months and uses a common broker designation. This is a standard Rule 144 disclosure rather than an operational or financial update.
TL;DR: Compliance-focused disclosure consistent with insider selling rules; signer affirms no undisclosed material information.
The form documents compliance with Rule 144 for the proposed disposition of shares acquired as deferred compensation. The attestation about lacking undisclosed material adverse information is standard and the absence of recent sales reduces concerns about aggregated disposition patterns. There is no indication in the filing of any governance or policy changes; it functions primarily as regulatory notice of a planned sale.